🔴 Novo Nordisk A/S is trading 4% down today as market re-evaluates Ozempic vs. Mounjaro competition

Novo Nordisk A/S is trading 4% down at $41.24 as investors react to fresh data comparing Ozempic and Eli Lilly’s Mounjaro in type 2 diabetes.

• Real-world findings presented at the American Diabetes Association’s 2026 Scientific Sessions showed higher-dose Ozempic achieved superior weight loss.
• Despite the positive results, the market appears to be re-pricing competitive expectations against Mounjaro.
• The stock decline reflects investor caution regarding Novo Nordisk's long-term market positioning in the GLP-1 space.